Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Market Data
|
People
|
Events
|
Multimedia
|
Science Abstracts
|
Scrip   
US prasugrel approval includes postmarketing study requirement on bleeding
20 July 2009
Sue Sutter
The US FDA has required Lilly/ Daiichi Sankyo to study whether platelet inhibition induced by Effient (prasugrel) can be reversed to stem bleeding. The postmarketing study requirement was contained in the agency's July 10th approval letter for the antiplatelet agent.
The sponsors have also agreed...



Please Login to read the full article.
 
Not a subscriber? Request a FREE Trial Subscribe to Scrip
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Scrip Features Other Informa Features
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm